Mauna Kea Technologies (ALMKT) Corporate presentation summary

Platform overview and clinical innovation

• Cellvizio enables real-time, cellular-level imaging during standard procedures, offering a new diagnostic standard for pancreatic cysts and IBS diagnostics.

• Over 20 FDA clearances, 200+ patents, and 1,200+ clinical papers support the platform's maturity and clinical adoption.

• Cellvizio is the only tool providing instant, visual confirmation of gut barrier reactions, addressing unmet needs in IBS diagnostics.

Commercial momentum and market expansion

• Core product sales have shown three consecutive quarters of double-digit growth, with the U.S. accounting for ~70% of total sales.

• International sales rebounded strongly, driven by CellTolerance adoption, especially in Germany and new territories.

• Strategic partnership with TaeWoong Medical USA expands U.S. reach and integrates imaging with therapy for pancreatic care.

Financial performance and outlook

• Operating losses reduced by 70% since 2020, with operating cash burn halved since 2022.

• Massive deleveraging achieved through a €27M debt reduction, restoring equity and shifting focus to growth.

• Profitability targeted by end-2027, with financial runway extended to early Q2 2027.